Skip to content

Firebrick Pharma recruits first patient for its confirmatory Phase 3 trial of Nasodine Nasal Spray as a treatment for the common cold.

It’s been a busy period for Firebrick Pharma as the Australian pharmaceutical company has now recruited the first patient for its Phase 3 trial for its Nasodine Nasal Spray as a treatment for the common cold.

Firebrick Pharma Executive Chairman Dr Peter Molloy joined Grafa’s Grady Wulff to discuss the recent announcement.

See more stories like this

download-the-app-today
0
    0
    Your Cart
    Your cart is emptyReturn to Shop
      Apply Coupon